Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report) and decreased the price target to $6.00 from $18.00.
Whitney Ijem’s rating is based on several key factors. Firstly, the positive clinical data from Tenaya Therapeutics’ TN-201 program for MYBPC3-associated hypertrophic cardiomyopathy (HCM) has shown promising results. The initial data from the first cohort of the Phase 1b/2 trial indicated a clear impact of the treatment on protein creation and disease progression, which is encouraging for future developments.
Additionally, Tenaya’s financial position has been strengthened by a recent public offering, providing a cash runway into mid-2026. This financial stability, combined with the progress in their gene therapy programs, supports the potential for future commercialization of their treatments. Despite a reduction in the price target from $18 to $6, the advancements in clinical trials and financial health underpin the Buy rating.
In another report released on March 11, Chardan Capital also maintained a Buy rating on the stock with a $9.00 price target.
TNYA’s price has also changed dramatically for the past six months – from $2.060 to $0.600, which is a -70.87% drop .
Questions or Comments about the article? Write to editor@tipranks.com